ESR1 and breast neoplasm: Luminal A/B tumors (70% of total breast tumors) express one or both hormone receptors, are treated by hormone therapy (mainly the ER antagonist tamoxifen or the anti-aromatase anastrozole) and considered to be of good prognosis.